---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-102222"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:19:43.834825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M

## Summary
- Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
- Omnibus equity plan share reserve raised from 470,000 to 1,400,000 shares, plus automatic annual increase.
- All four director nominees re-elected; ratification of Salberg & Company as auditor approved.
- Reverse split proposal received 3,896,499 for vs 1,253,332 against; plan amendment got 1,343,678 for vs 514,675 against.

## SEC filing metadata
- accession: 0001213900-25-102222
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/0001213900-25-102222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390025102222/ea0262461-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-102222
- JSON: https://secwatch.observer/filing/0001213900-25-102222.json
- Plain text: https://secwatch.observer/filing/0001213900-25-102222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.